Differential sensitivities of recombinant human topoisomerase IIα and β to various classes of topoisomerase II interacting agents

被引：25

作者：

Perrin, D ^{[1
]}

van Hille, B ^{[1
]}

Hill, BT ^{[1
]}

机构：

[1] Ctr Rech Pierre Fabre, Dept Expt Cancerol 1, Div Expt Cancerol 1, F-81106 Castres, France

来源：

BIOCHEMICAL PHARMACOLOGY | 1998年 / 56卷 / 04期

关键词：

topoisomerase II alpha; topoisomerase II beta; catalytic activity; antitumour agents; DNA-decatenation; topoisomerase II-interacting agents;

D O I：

10.1016/S0006-2952(98)00082-3

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

A series of topoisomerase-interacting antitumour agents were tested for their ability to differentially inhibit the catalytic activity of either topoisomerase (TOPO) II alpha or beta, as judged by a DNA decatenation assay. The alpha form, relative to the beta isoform, proved 1 to 3 times more sensitive to nonintercalating complex-stabilizing TOPO II-interacting agents (etoposide and derivatives) and up to 18 times more sensitive to non complex-stabilizing inhibitors of TOPO II ((+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane [ICRF 159] and meso-2,3-bis(3,5-dioxopiperazine-1-yl)butane [ICRF 193]). However, the beta form of the enzyme appeared 1 to 3 times more sensitive to intercalating TOPO II-interacting agents (daunorubicin, aclarubicin and mitoxantrone). A possible implication of these data are that rumours preferentially expressing either the oc or the beta isoform may be differentially responsive to various classes of TOPO II-interacting agents. BIOCHEM PHARMACOL 56;4:503-507, 1998. (C) 1998 Elsevier Science Inc.

引用

页码：503 / 507

页数：5

共 22 条

[11] CLEAVAGE OF STRUCTURAL PROTEINS DURING ASSEMBLY OF HEAD OF BACTERIOPHAGE-T4 [J].

LAEMMLI, UK .

NATURE, 1970, 227 (5259) :680-+

[12] THE ANTILEUKEMIC ALKALOID FAGARONINE IS AN INHIBITOR OF DNA TOPOISOMERASE-I AND TOPOISOMERASE-II [J].

LARSEN, AK ;

GRONDARD, L ;

COUPRIE, J ;

DESOIZE, B ;

COMOE, L ;

JARDILLIER, JC ;

RIOU, JF .

BIOCHEMICAL PHARMACOLOGY, 1993, 46 (08) :1403-1412

[13] Complementation of temperature-sensitive topoisomerase II mutations in Saccharomyces cerevisiae by a human TOP2 beta construct allows the study of topoisomerase II beta inhibitors in yeast. [J].

Meczes, EL ;

Marsh, KL ;

Fisher, LM ;

Rogers, MP ;

Austin, CA .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1997, 39 (04) :367-375

[14] Cell cycle-coupled relocation of types I and II topoisomerases and modulation of catalytic enzyme activities [J].

Meyer, KN ;

Kjeldsen, E ;

Straub, T ;

Knudsen, BR ;

Hickson, ID ;

Kikuchi, A ;

Kreipe, H ;

Boege, F .

JOURNAL OF CELL BIOLOGY, 1997, 136 (04) :775-788

[15] THE MECHANISMS OF DNA TOPOISOMERASES [J].

ROCA, J .

TRENDS IN BIOCHEMICAL SCIENCES, 1995, 20 (04) :156-160

[16] Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle [J].

Sehested, M ;

Jensen, PB .

BIOCHEMICAL PHARMACOLOGY, 1996, 51 (07) :879-886

[17] CLONING AND SEQUENCING OF CDNA-ENCODING HUMAN DNA TOPOISOMERASE-II AND LOCALIZATION OF THE GENE TO CHROMOSOME REGION 17Q21-22 [J].

TSAIPFLUGFELDER, M ;

LIU, LF ;

LIU, AA ;

TEWEY, KM ;

WHANGPENG, J ;

KNUTSEN, T ;

HUEBNER, K ;

CROCE, CM ;

WANG, JC .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (19) :7177-7181

[18] The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues [J].

Turley, H ;

Comley, M ;

Houlbrook, S ;

Nozaki, N ;

Kikuchi, A ;

Hickson, ID ;

Gatter, K ;

Harris, AL .

BRITISH JOURNAL OF CANCER, 1997, 75 (09) :1340-1346

[19]

WASSERMAN RA, 1993, CANCER RES, V53, P3591

[20] Differential expression of DNA topoisomerase II alpha and -beta in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC(4) [J].

Withoff, S ;

deVries, EGE ;

Keith, WN ;

Nienhuis, EF ;

vanderGraaf, WTA ;

Uges, DRA ;

Mulder, NH .

BRITISH JOURNAL OF CANCER, 1996, 74 (12) :1869-1876

← 1 2 3 →